Skip to main content

How COVID-19 Pandemic Will Impact on Pneumonia Therapeutics Market Growth and Demand in 2020 and Coming Future?

  The pneumonia therapeutics market is predicted to have a positive impact in 2020. Increasing cases of pneumococcal disease is predicted to drive the market in the forecast period. Pneumonia is mostly caused due to the infection in the lungs. At present the symptoms of coronavirus are most similar to that of pneumonia due to which most of the companies are focusing more on their research and development activities to launch new products to treat both the deadly diseases. For instance, in July 2020 NABRIVA received European approval for XENLETA (lefamulin) for treatment of community-acquired pneumonia (CAP). XENLETA is the first new antibiotic approved for patients with CAP in Europe. During this unpredicted situation, we are helping our clients in understanding the impact of COVID19 on the global market.

According to a study conducted by Research Dive, the global pneumonia therapeutics market is expected to register a revenue of $3,147.7 million till 2027, growing at a rate of 8.2% CAGR during, 2020-2027. The global market is classified on the basis of drug class, age group, and infection type and distribution channel. The report provides detailed information about drivers, opportunities, restraints, segmental analysis and competitive players of the market.

Factors Affecting the Market Growth

As per our analyst, increasing cases of pneumonia across the globe is predicted to be the major driving factor for the market in the projection period. Moreover, lack of awareness among the population about the pneumonia treatment is predicted to hinder the market growth in the forecast period.

Antiviral Drugs is Predicted to Have the Highest Market Share

On the basis of drug class, the pneumonia therapeutics market is further segmented into antifungal drugs, antiviral drugs and antibacterial drugs. Antiviral drugs is predicted to generate a revenue of $1,621.1 by 2027 with a CAGR of 8.6% in the projected timeframe. Pneumonia is a critical lung disorder which occurs mainly due to flu, several antiviral drugs helps to minimize the seriousness of the flu and helps in getting recover at a faster rate as compared to others medications due to which antiviral drugs segment is predicted to boost the overall market in the projected time frame.

Geriatric Segment is Predicted to Have Highest Growth Rate

On the basis of age group, the pneumonia therapeutics market is further segmented into geriatric, adult, and pediatric. Geriatric segment is predicted to generate a revenue of $1,215.0 by 2027 with a CAGR of 8.7% in the projected timeframe. Geriatric population has a weak immune system. There are high chances of being affected by pneumonia among the geriatric population due to which it is predicted to boost the segment in the forecast period.

Community-Acquired Pneumonia is Predicted to Grow Enormously

On the basis of infection type, the pneumonia therapeutics market is further segmented into ventilator-associated pneumonia (VAP), community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP). Community-acquired pneumonia segment is predicted to generate a revenue of $1,935.8 by 2027 with a CAGR of 8.5% in the projected timeframe. Community-acquired pneumonia generally occurs where people live in crowded places. Growing cases of community-acquired pneumonia especially in younger generation is predicted to boost the segment market in the forecast period.

Retail Pharmacies is Predicted to be the Most Lucrative Segment

On the basis of distribution channel, the pneumonia therapeutics market is further segmented into retail pharmacies, online pharmacies, and hospital pharmacies. Retail Pharmacies is predicted to generate a revenue of $1,284.2 by 2027 with a CAGR of 9.1% in the projected timeframe. The retail pharmacies segment is predicted to experience a boost due to the presence of large amount of brick and mortar store which gives a better advantage of accessibility, lower costs due to economies of scale and better services.

Regional Breakdown of the Market

On the basis of region, the pneumonia therapeutics market is further segmented into North America, Europe, Asia-Pacific and LAMEA. North America region market is predicted to generate a revenue of $1,023.0 by 2027 with a CAGR of 7.2% in the projected timeframe. Increasing geriatric population and presence of large number of pharmaceutical companies is predicted to drive the region market in the estimated time. Moreover, increasing research and development by majority of the companies is predicted to boost the region market in the forecast period

Top 9 Prominent players operating in the Global Pneumonia Therapeutics Market include:

1. Mylan
2. Novartis Lupin Pharmaceuticals
3. GlaxoSmithKline
4. Cipla
5. Abbott
6. Sanofi
7. Merck
8. Bayer
9. Allergan

Reference: https://www.researchdive.com/press-release/pneumonia-therapeutics-market.html

Contact Us:

Mr. Abhishek Paliwal
Research Dive
30 Wall St. 8th Floor, New York
NY 10005 (P)
+ 91 (788) 802-9103 (India)
+1 (917) 444-1262 (US) Toll
Free : +1 -888-961-4454
Email: support@researchdive.com
LinkedIn: https://www.linkedin.com/company/research-dive
Twitter: https://twitter.com/ResearchDive
Facebook: https://www.facebook.com/Research-Dive
Blog: https://www.researchdive.com/blog
Follow us on: https://covid-19-market-insights.blogspot.com

Comments

Popular posts from this blog

Growth Outlook: Healthcare Gamification Market Expand their Businesses with New Investments

   Download FREE Sample The healthcare gamification market share is predicted to grow at a CAGR of 11.9% by generating a revenue of $47,281.5 Million by 2026. Gamification includes applying the techniques used in game, mechanics of game, and game style in non-gaming applications to engage the audience and make the dull task into more fun and engaging. Basically it is an application of elements in video games, which helps to solve the everyday problem and enables the user to change the behavior, develop skills and enable innovation in health care. The  goal of the gamification  is to change the behavior of the patient. The increase in the wearables and health & wellness app with gamification is the strong sign that the people are liking it. The increase in the usage of digitalization and the technology adoption are expected to drive the healthcare gamification market. Many companies are using the digital platform for the people to check their health data. For...

COVID-19 Impact: What Challenges Hand Sanitizer Market May See In Next 5 Years?

   Inquire Here Before Purchase and Get FREE Sample The communal transmission of COVID-19 has created a significant impact on the hand sanitizer market growth, throughout the projected timeframe. The growth of the global hand sanitizer market is mainly driven by the rising concern about personal safety among the customers. Furthermore, the extensively growing prevalence of viral disorders globally is also creating a huge demand for hand sanitizers, in the review period. Though the businesses across the globe have strictly imposed lockdown in order to reduce the impact of the pandemic spread, the  global hand sanitizer industry  has shown exponential growth. The ventures involved with hand sanitizer production are adopting numerous strategic steps like product & technology advancements, strategic tie-ups. For example, in June 2020, Procter & Gamble (P&G), has made an announcement to launch of newly invented ‘safeguard sanitizer’. In addition, the enterpris...

What are the Left Atrial Appendage Closure Devices Market Key Insights and COVID-19 Business Impact?

   Download FREE Sample Connect with Analyst The COVID-19 outbreak has significantly affected the global left atrial appendage closure devices market. As per American Heart Association, people having high blood pressure, heart valve disease and congenital heart diseases are expected to develop severe coronavirus symptoms. Also, this virus can generate heart strokes through weakening of muscles of the heart. These fators will boost the demand for left atrial appendage closure divices and surge the market growth during the pandemic. Furthermore, the leading manufactures in the global market are adopting various strategies such as product innovations and partnerships to increase their market share in the overall industry. For example, in July 2020, Boston Scientific Corporation announced that the “Watchman FLX left atrial appendage closure device” has been approved by U.S. Food and Drug Administration, which is used to minimize the threat of heart stroke in patients. The stroke r...